Dyax Corp. to Participate in the Needham & Company 11th Annual Healthcare Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--
Corp. (NASDAQ: DYAX) announced today that executive management will
participate in the Needham and Company 11th Annual Healthcare
Conference, being held April 3-4, 2012 at the New York Palace Hotel in
New York City. Gustav Christensen, President and Chief Executive Officer
of Dyax, will present on Tuesday, April 3rd at 1:20 PM (ET).
Mr. Christensen will provide a corporate update regarding the Company's
two key value drivers - the angioedema franchise and the Licensing and
Funded Research Program (LFRP).
The Dyax presentation will be webcast live and may be accessed by
visiting the Investor Relations section of the company website at www.dyax.com.
The webcast will also be available on the Dyax website for a limited
period of time following the conference.
Dyax is a fully integrated biopharmaceutical company focused on the
development and commercialization of novel biotherapeutics for unmet
medical needs. Dyax's lead product, ecallantide, has been approved under
the brand name KALBITOR® in the United States for the treatment of acute
attacks of hereditary angioedema (HAE) in patients 16 years of age and
Dyax is commercializing KALBITOR in the United States independently, and
establishing strategic collaborations to develop and commercialize
ecallantide for the treatment of HAE in key regions worldwide.
Currently, Dyax has agreements for regions including Europe, Japan,
Russia, the Middle East, Israel, North Africa, Australia, New Zealand,
Latin America (excluding Mexico) and the Caribbean. Dyax is also
exploring other potential indications for ecallantide, either alone or
through collaborations, including drug-induced angioedema.
Ecallantide and other compounds in Dyax's pipeline were identified using
its patented phage display technology, which rapidly selects compounds
that bind with high affinity and specificity to therapeutic targets.
Dyax leverages this technology broadly through the Licensing and Funded
Research Program (LFRP), which has over 70 revenue generating licenses
and collaborations for therapeutic discovery, as well as for affinity
separations, diagnostic imaging, and research reagents. The success of
the Company's LFRP portfolio is illustrated by the program's advanced
licensee pipeline that includes 18 candidates in clinical development.
Of those candidates, four are in Phase 3 clinical trials, four are in
Phase 2 and ten are in Phase 1.
Dyax is headquartered in Burlington, Massachusetts. For online
information about Dyax Corp., please visit www.dyax.com.
George Migausky, 617-250-5733
Chief Financial Officer
Manager, Investor Relations and
Source: Dyax Corp.
News Provided by Acquire Media
Close window | Back to top